Cargando…

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy

Activation of the innate immune system and natural killer (NK) cells has been a key effort in cancer immunotherapy research. Here, we report a nanoparticle-based trispecific NK cell engager (nano-TriNKE) platform that can target epidermal growth factor receptor (EGFR)–overexpressing tumors and promo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Au, Kin Man, Park, Steven I., Wang, Andrew Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455497/ https://www.ncbi.nlm.nih.gov/pubmed/32923587 http://dx.doi.org/10.1126/sciadv.aba8564

Ejemplares similares

Systemic Delivery of mPEG‐Masked Trispecific T‐Cell Nanoengagers in Synergy with STING Agonists Overcomes Immunotherapy Resistance in TNBC and Generates a Vaccination Effect
por: Shen, Ming, et al.
Publicado: (2022)

Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells
por: Kimura, Kouki, et al.
Publicado: (2023)

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
por: Cheng, Ying, et al.
Publicado: (2020)

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2022)

Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture
por: Bogen, Jan P., et al.
Publicado: (2021)

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells
por: Arvindam, Upasana Sunil, et al.
Publicado: (2020)

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections
por: Promsote, Wanwisa, et al.
Publicado: (2023)

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
por: Steinhardt, James J., et al.
Publicado: (2018)

Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.
por: Eggermont, A. M., et al.
Publicado: (1988)

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

Targeted delivery of liposomal chemoimmunotherapy for cancer treatment
por: Liu, Yusheng, et al.
Publicado: (2022)

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma
por: Au, Kin Man, et al.
Publicado: (2020)

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
por: Rothenberger, Sylvia, et al.
Publicado: (2022)

Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
por: Harwardt, Julia, et al.
Publicado: (2023)

Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer
por: Iyoda, Tomonori, et al.
Publicado: (2023)

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
por: Warmuth, Stefan, et al.
Publicado: (2021)

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
por: Ding, Ziqiang, et al.
Publicado: (2023)

Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy
por: Wang, Meng, et al.
Publicado: (2022)

Natural killer cells and natural killer T cells in Lyme arthritis
por: Katchar, Kia, et al.
Publicado: (2013)

Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
por: Abrams, R. E., et al.
Publicado: (2022)

Analysis of [Gossypium capitis-viridis × (G.hirsutum × G.australe)(2)] Trispecific Hybrid and Selected Characteristics
por: Chen, Di, et al.
Publicado: (2015)

The impact of proline isomerization on antigen binding and the analytical profile of a trispecific anti-HIV antibody
por: Masiero, Alessandro, et al.
Publicado: (2020)

Natural killer cell immunotherapy to target stem-like tumor cells
por: Grossenbacher, Steven K., et al.
Publicado: (2016)

Targeting Natural Killer Cells for Tumor Immunotherapy
por: Zhang, Cai, et al.
Publicado: (2020)

Modeling Natural Killer Cell Targeted Immunotherapies
por: Lopez-Lastra, Silvia, et al.
Publicado: (2017)

Targeting Natural Killer T Cells in Solid Malignancies
por: Ingram, Zewde, et al.
Publicado: (2021)

Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers
por: Messaoudene, Meriem, et al.
Publicado: (2017)

Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells
por: Luna, Jesus I., et al.
Publicado: (2019)

Correction for Khan et al., “Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry”
por: Khan, Salar N., et al.
Publicado: (2019)

Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform
por: Pekar, Lukas, et al.
Publicado: (2020)

A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region
por: Hajduczki, Agnes, et al.
Publicado: (2020)

A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies
por: Wang, Bo, et al.
Publicado: (2022)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins
por: Debelec-Butuner, Bilge, et al.
Publicado: (2022)

Roles of Natural Killer T Cells and Natural Killer Cells in Kidney Injury
por: Uchida, Takahiro, et al.
Publicado: (2019)

Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
por: Thibaudin, Marion, et al.
Publicado: (2023)

MAPK signaling regulates the efficacy of chemoimmunotherapy
por: Ghiringhelli, François
Publicado: (2022)

Pharmacological targeting of natural killer cells for cancer immunotherapy
por: Miyazato, Kiho, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9k3b5vkjgfadg2gbi76hsr7bt8